• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

上尿路尿路上皮癌中人表皮生长因子受体2状态的评估:一项使用双色原位杂交和免疫组织化学的研究。

Assessment of human epidermal growth factor receptor 2 status in urothelial carcinoma of the upper urinary tract: a study using dual-color in situ hybridization and immunohistochemistry.

作者信息

Vershasselt-Crinquette Marie, Colin Pierre, Ouzzane Adil, Gnemmi Viviane, Robin Yves-Marie, Aubert Sebastien, Villers Arnauld, Leroy Xavier

机构信息

Institute of Pathology, Biology-Pathology Center, Centre Hospitalier Regional Universitaire and University Lille II, Lille, France.

出版信息

Appl Immunohistochem Mol Morphol. 2012 Jul;20(4):363-6. doi: 10.1097/PAI.0b013e318241cab9.

DOI:10.1097/PAI.0b013e318241cab9
PMID:22495372
Abstract

AIM

Upper urinary tract urothelial carcinoma (UUTUC) is an uncommon neoplasm frequently discovered at a high-stage disease. The prognosis of disseminated UUTUCs is poor despite the use of platinum-based chemotherapy. The aim of the study was to evaluate HER2 overexpression and amplification in a series of 83 UUTUCs.

MATERIALS AND METHODS

All tumors were formalin fixed. TNM stage, grade, lymphovascular invasion, surgical margins, morphologic variants were reviewed by 2 pathologists. All tumors were immunostained with anti-HER2 antibody. HER2 gene amplification was determined by dual-color in situ hybridization. Gene amplification was defined by an HER2/CEN 17 ratio >2.2.

RESULTS

HER2 immunostaining was observed in 33/83 tumors. Twelve cases were 2+ score and 2 cases were 3+ score. HER2 in situ hybridization was evaluable in 75/83 cases. Amplification was observed in 6 (7%) cases. All amplified tumors were of high grade and 4/6 were stage pT3. A strong correlation between HER2 overexpression and amplification was noted (P<0.0001). HER2 overexpression and amplification were correlated with the pN+ stage but not with specific survival or recurrence.

CONCLUSIONS

These results suggest that HER2 amplification is a rare event in UUTUC but may be of interest for targeted therapy in selected high-grade and high-stage tumors.

摘要

目的

上尿路尿路上皮癌(UUTUC)是一种不常见的肿瘤,常在疾病晚期被发现。尽管使用了铂类化疗,但播散性UUTUC的预后较差。本研究的目的是评估83例UUTUC中HER2的过表达和扩增情况。

材料与方法

所有肿瘤均用福尔马林固定。两名病理学家对TNM分期、分级、淋巴管浸润、手术切缘、形态学变异进行了评估。所有肿瘤均用抗HER2抗体进行免疫染色。通过双色原位杂交测定HER2基因扩增情况。基因扩增定义为HER2/CEN 17比值>2.2。

结果

83例肿瘤中有33例观察到HER2免疫染色。12例评分为2+,2例评分为3+。83例中有75例可进行HER2原位杂交评估。6例(7%)观察到扩增。所有扩增肿瘤均为高级别,6例中有4例为pT3期。注意到HER2过表达与扩增之间存在强相关性(P<0.0001)。HER2过表达和扩增与pN+期相关,但与特定的生存率或复发无关。

结论

这些结果表明,HER2扩增在UUTUC中是罕见事件,但对于选定的高级别和晚期肿瘤的靶向治疗可能具有意义。

相似文献

1
Assessment of human epidermal growth factor receptor 2 status in urothelial carcinoma of the upper urinary tract: a study using dual-color in situ hybridization and immunohistochemistry.上尿路尿路上皮癌中人表皮生长因子受体2状态的评估:一项使用双色原位杂交和免疫组织化学的研究。
Appl Immunohistochem Mol Morphol. 2012 Jul;20(4):363-6. doi: 10.1097/PAI.0b013e318241cab9.
2
HER2 protein overexpression and gene amplification in upper urinary tract urothelial carcinoma-an analysis of 171 patients.HER2蛋白过表达与基因扩增在上尿路尿路上皮癌中的研究——171例患者分析
Int J Clin Exp Pathol. 2014 Jan 15;7(2):699-708. eCollection 2014.
3
Sarcomatoid carcinoma of the upper urinary tract: clinical outcome and molecular characterization.上尿路肉瘤样癌:临床结局与分子特征
Hum Pathol. 2009 Feb;40(2):211-7. doi: 10.1016/j.humpath.2008.07.003. Epub 2008 Sep 16.
4
HER2 and TOP2A Gene Amplification and Protein Expression in Upper Tract Urothelial Carcinomas.上尿路尿路上皮癌中HER2和TOP2A基因扩增及蛋白表达
Pathol Oncol Res. 2018 Jul;24(3):575-581. doi: 10.1007/s12253-017-0260-0. Epub 2017 Jul 28.
5
Human Epidermal Growth Factor Receptor 2 Overexpression in Micropapillary and Other Variants of Urothelial Carcinoma.人表皮生长因子受体 2 在微乳头状和其他变异型尿路上皮癌中的过表达。
Eur Urol Focus. 2018 Apr;4(3):399-404. doi: 10.1016/j.euf.2016.06.007. Epub 2016 Jun 21.
6
In situ analysis of HER2 mRNA in gastric carcinoma: comparison with fluorescence in situ hybridization, dual-color silver in situ hybridization, and immunohistochemistry.原位分析胃癌中的 HER2 mRNA:与荧光原位杂交、双色银原位杂交和免疫组织化学的比较。
Hum Pathol. 2013 Apr;44(4):487-94. doi: 10.1016/j.humpath.2012.06.022. Epub 2012 Oct 16.
7
Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression.Her2 扩增可区分具有高进展风险的非肌肉浸润性膀胱癌的亚群。
J Clin Pathol. 2013 Feb;66(2):113-9. doi: 10.1136/jclinpath-2012-200944. Epub 2012 Oct 19.
8
The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.HER2/neu过表达/扩增在乳腺导管原位癌进展为浸润性癌过程中的作用。
Mod Pathol. 2002 Dec;15(12):1318-25. doi: 10.1097/01.MP.0000038462.62634.B1.
9
Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.采用 INFORM HER2 双色原位杂交技术对人表皮生长因子受体 2 检测进行验证和工作流程优化。
Hum Pathol. 2013 Nov;44(11):2590-6. doi: 10.1016/j.humpath.2013.07.005. Epub 2013 Sep 25.
10
[Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].[人表皮生长因子受体2/神经生长因子(Her2/neu)在局部晚期膀胱癌中的表达:对分子靶向治疗的意义]
Aktuelle Urol. 2005 Sep;36(5):423-9. doi: 10.1055/s-2004-830253.

引用本文的文献

1
Blood-, Tissue- and Urine-Based Prognostic Biomarkers of Upper Tract Urothelial Carcinoma.基于血液、组织和尿液的上尿路尿路上皮癌预后生物标志物
Diagnostics (Basel). 2024 Aug 31;14(17):1927. doi: 10.3390/diagnostics14171927.
2
HER2 expression in upper tract urothelial carcinoma and the relationship with clinicopathological characteristics-an analysis of 155 patients in Southwest China.中国西南部 155 例上尿路上皮癌中 HER2 表达与临床病理特征的关系分析。
World J Urol. 2024 Sep 13;42(1):521. doi: 10.1007/s00345-024-05222-8.
3
Amplification as a Predictive and Prognostic Biomarker in Upper Tract Urothelial Carcinoma.
作为上尿路尿路上皮癌预测和预后生物标志物的扩增
Cancers (Basel). 2023 Apr 22;15(9):2414. doi: 10.3390/cancers15092414.
4
Tissue-based molecular markers in upper tract urothelial carcinoma and their prognostic implications.上尿路尿路上皮癌的组织分子标志物及其预后意义。
Int Braz J Urol. 2018 Jan-Feb;44(1):22-37. doi: 10.1590/S1677-5538.IBJU.2017.0204.
5
HER2 and TOP2A Gene Amplification and Protein Expression in Upper Tract Urothelial Carcinomas.上尿路尿路上皮癌中HER2和TOP2A基因扩增及蛋白表达
Pathol Oncol Res. 2018 Jul;24(3):575-581. doi: 10.1007/s12253-017-0260-0. Epub 2017 Jul 28.
6
Comparison of the FDA and ASCO/CAP Criteria for HER2 Immunohistochemistry in Upper Urinary Tract Urothelial Carcinoma.FDA与ASCO/CAP标准在上尿路尿路上皮癌HER2免疫组化中的比较
J Pathol Transl Med. 2016 Nov;50(6):436-441. doi: 10.4132/jptm.2016.07.12. Epub 2016 Oct 10.
7
HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC).人表皮生长因子受体2(HER2)过表达与上尿路尿路上皮癌(UTUC)患者的不良预后相关。
World J Urol. 2017 Feb;35(2):251-259. doi: 10.1007/s00345-016-1871-x. Epub 2016 Jun 7.
8
Human epidermal growth factor receptor 2 expression in urothelial carcinoma of the renal pelvis: correlation with clinicopathologic parameters.人表皮生长因子受体2在肾盂尿路上皮癌中的表达:与临床病理参数的相关性
Int J Clin Exp Pathol. 2014 Apr 15;7(5):2544-50. eCollection 2014.
9
HER2 protein overexpression and gene amplification in upper urinary tract urothelial carcinoma-an analysis of 171 patients.HER2蛋白过表达与基因扩增在上尿路尿路上皮癌中的研究——171例患者分析
Int J Clin Exp Pathol. 2014 Jan 15;7(2):699-708. eCollection 2014.
10
Distinct patterns and behaviour of urothelial carcinoma with respect to anatomical location: how molecular biomarkers can augment clinico-pathological predictors in upper urinary tract tumours.关于解剖部位的尿路上皮癌的不同模式和行为:分子生物标志物如何在上尿路肿瘤中增强临床病理预测因子。
World J Urol. 2013 Feb;31(1):21-9. doi: 10.1007/s00345-012-0946-6. Epub 2012 Sep 18.